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Abstract
Acute periods of pulmonary exacerbation are the single most important cause of morbidity in
cystic fibrosis patients, and may be associated with a loss of lung function. Intervening prior to the
onset of a substantially increased inflammatory response may limit the associated damage to the
airways. While a number of biomarker assays based on inflammatory markers have been
developed, providing useful and important measures of disease during these periods, such factors
are typically only elevated once the process of exacerbation has been initiated. Identifying
biomarkers that can predict the onset of pulmonary exacerbation at an early stage would provide
an opportunity to intervene before the establishment of a substantial immune response, with major
implications for the advancement of cystic fibrosis care. The precise triggers of pulmonary
exacerbation remain to be determined; however, the majority of models relate to the activity of
microbes present in the patient's lower airways of cystic fibrosis. Advances in diagnostic
microbiology now allow for the examination of these complex systems at a level likely to identify
factors on which biomarker assays can be based. In this article, we discuss key considerations in
the design and testing of assays that could predict pulmonary exacerbations.
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The need for biomarkers of pulmonary exacerbation in cystic fibrosis
Cystic fibrosis (CF) lung disease is characterized by a self-perpetuating cycle of airway
obstruction, chronic bacterial infection and vigorous inflammation that results in
bronchiectasis. Over 90% of people with CF die as a consequence of progressive lung
damage resulting from bacterial infection [1,2]. CF patients typically have periods of clinical
remission interspersed with acute episodes of increased respiratory symptoms, known as
cystic fibrosis pulmonary exacerbation (CFPE). CFPEs are a major cause of morbidity for
CF patients [3] and are often accompanied by a decline in lung function that may not be
recovered following treatment [4,5]. CFPEs and associated lung damage have a major
impact on quality of life [6–9], short-term mortality [10–13] and healthcare expenditure
[10]. However, the lack of a specific disease marker or a unifying, commonly-accepted
indicator to initiate treatment for a CFPE hampers the improvement of patient care. There is,
therefore, substantial effort directed towards finding a marker to enable prompt diagnosis
and treatment of CFPEs before irreversible lung damage occurs.
A key problem in diagnosing CFPE is the lack of a consensus definition of what it
constitutes. Diagnosis typically revolves around a clinician's decision to treat a constellation
of symptoms [14], including cough, sputum production, dyspnea, decreased energy level and
appetite, weight loss and decreases in spirometric parameters [15]. There is a continuing
debate as to which combination of these measures most accurately represents a significant
clinical change necessitating intervention [16]. CF patients differ widely in the way in which
they manifest their condition [17] and the large number of treatment options may have side
effects that mask or mimic some clinical signs [18–20]. Increasingly, patients who appear or
feel ‘not quite right’ are being treated with antibiotics to prevent the development of more
worrying symptoms [16]. The treatment of patients with mild symptoms that do not yet meet
typical CFPE definitions might, in some cases, reduce the incidence of CFPE over the long
term [21,22]. However, the consequentially increased antibiotic use and the serious
accompanying side effects of such an approach are a significant cause for concern.
Patient-reported symptoms might be an important complement to physician-assessed clinical
signs in the diagnosis of CFPE, and newly developed diaries are currently being validated
for this purpose [15,17,23,24]. However, patient-reported outcome scores are not without
drawbacks. Subjective judgments about symptom severity differ significantly between
patients [25], and could potentially be influenced by the desire to more firmly control
therapy.
It would be ideal if biomarkers could be identified that had the capability of directly
reflecting objective disease activity rather than relying entirely on clinical markers. Factors
involved early in the CFPE initiation pathway could prove useful as predictive markers,
allowing earlier intervention. The aim of early intervention would be to quickly reduce the
development of a full inflammatory response and to shorten and reduce the severity of the
CFPE, with the hope of preventing the development of irreversible lung damage. In this
way, an effective and reproducible diagnostic marker for the early stages of a CFPE could
offer the exciting possibility of disease-modifying therapy that could prevent permanent loss
of lung function and the associated morbidity and mortality.
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Bacterial infections in the CF airways are currently monitored through routine microbiology.
While useful in the long-term surveillance of disease progression, these data are unlikely to
provide sufficient detail to be predictive of CFPE onset. The application of molecular
diagnostics to monitor biomarkers of bacterial infection continues to expand [26–28]. The
increasing availability of commercial assays, in conjunction with a growing recognition of
the utility of such molecular diagnostics in the characterization of clinical infections, means
that routine surveillance in the management of CF respiratory disease using these methods
may now be possible. However, which biomarkers are to be measured requires careful
consideration.
In this article, we examine the potential of microbial factors to provide biomarkers for the
early detection of CFPE onset, as well as the challenges that must be overcome for such
molecular diagnostic surveillance to be implemented routinely.
Cystic fibrosis pulmonary exacerbation
The reasons for the occurrence of periods of CFPE are often not known, although a number
of potential causes have been suggested (Box 1). These include the acquisition of new
strains of bacterial species [29], the expansion of existing bacterial populations in the
airways [29], blooms of planktonic bacterial cells released from biofilm populations [30],
the expression of bacterial virulence factors [31], viral infections [32,33] and ambient air
pollution (Box 1) [34]. Despite the lack of clarity regarding the triggers of CFPE, once
initiated, the typical increase in severity of respiratory signs and symptoms is thought to
reflect an upregulation of local inflammatory responses. As highlighted by a number of
review articles, this inflammatory response is complex and multifactorial [17,23,24,35].
Broadly, CF airway disease is considered to be dominated by persistent neutrophilic
infiltration, with elevated IL-8 and neutrophil elastase in airway secretions [36–41]. There is
evidence that proinflammatory cytokines and other mediators are abnormally elevated in CF
patients, relative to the burden of infection [42]; it has been suggested that dysregulation
directly results from the underlying CF defect [41,43,44]. However, inflammation is
increased by local airway epithelium–pathogen interactions and is elevated during CFPE
[41].
The elevated inflammatory response that characterizes CFPE forms a positive-feedback loop
(Figure 1). Activated neutrophils release large amounts of elastase and other proteases that
over-whelm the local host defenses [15]. Furthermore, as these neutrophils break down, they
release large amounts of high-molecular-weight DNA that further increases the viscosity of
the endobronchial secretions, which hinders mucociliary clearance [45]. In this way, a
vicious cycle of chronic infection and inflammation occurs that encourages persistence of
pathogens, promotes obstruction of the airway lumen and causes the destruction of airway
wall architecture [15,46].
CFPE biomarkers
Biomarkers enable objective measurement and evaluation of “normal biologic processes,
pathogenic processes, and pharmacologic responses to a therapeutic intervention” [47]. They
have been shown to be useful in the diagnosis and characterization of a wide range of
clinical conditions, including cardiovascular, renal and metabolic diseases, as well as sepsis
and cancer [48–50]. Biomarkers should reflect biological activity and correlate with
established clinical outcome measures, such as how a patient feels, functions or survives
[51–53]. Their potential use in CF is particularly attractive given the diverse manifestations
of CF airway disease and the response to therapy among individual CF patients.
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Key biomarker characteristics that must be considered when designing assays for CFPE
generally have been set out by Mayer-Hamblett et al. [53]. However, some of these
considerations are more relevant to the use of biomarkers as early indicators of CFPE onset.
Biomarkers useful in this context must be considered on the basis of two key areas; the
degree to which they reflect biologically informative processes predictive of CFPE onset,
and their suitability for use as a routine diagnostic tool.
Reflection of biologically informative processes predictive of CFPE onset
Biomarkers must consistently show a change in level prior to the onset of CFPE when
compared with levels during clinical stability, at least among a subset of patients or
exacerbations. Determining such a change relies on defining the point at which a patient is
experiencing CFPE. However, in the absence of a consensus definition for CFPE, biomarker
levels can only be correlated with an increase in accepted clinical markers and symptom
scores. Although measurements of sputum inflammatory biomarkers obtained from the same
patient on different occasions have been shown to be reproducible (although not specifically
as predictors of CFPE), they can vary considerably between patients [54,55]. It is therefore
important that the baseline values of such clinical markers are recognized as specific to
individual patients, and that the assay can cover the effective range of clinically relevant test
results.
Useful biomarkers should have a turnover rate that allows them to reflect short-term changes
within the airways, but be sufficiently stable for accurate and reproducible measurement.
Biomarkers that are highly unstable may be present for a very short period of time and may
therefore only be detectable through frequent sampling. Furthermore, such instability could
lead to appreciable biomarker degradation during sample handling. By contrast, highly
stable biomarkers may accumulate over time in the airways in such a way that they do not
reflect short-term changes in disease or return to baseline levels following successful
treatment.
Suitability for use as a routine diagnostic tool
It is essential that the biomarker being measured is easily available from samples that can be
routinely collected from patients, such as blood, urine, exhaled breath (EB), saliva or
sputum. Inflammation in the CF lung appears to be primarily driven by local stimuli,
mediators and chemoattractants, and is not the local effect of a systemic inflammatory
reaction [56]. As such, systemic indicators of inflammation are likely to have low sensitivity
and show only modest increases during acute exacerbations. Blood-based biomarkers are
therefore less appropriate for diagnosing the onset of CFPE. Sputum is readily obtainable in
the vast majority of adult CF patients and has been shown to be a useful basis for
characterizing CF airway infection [57–59]. However, it should be noted that owing to the
uneven distribution of infection within the CF lower airways, performing frequent assays is
necessary in order to minimize sampling bias [60,61]. EB and EB condensate (EBC) have
been used as samples for measuring biomarkers in a range of respiratory conditions [62,63].
While some concerns have been raised about the sensitivity and reproducibility of these
sample types [63], they are noninvasive and easily collectable. EB and EBC samples have
been used for the measurement of a number of biomarkers in CF patients, including nitric
oxide [64–66], condensate acidity, nitrate, nitrite, 8-isoprostane, hydrogen peroxide and
IFN-γ [67].
Since analysis will not be performed immediately in most instances, biomarkers must be
stable at room temperature or have the capacity to be stabilized with the addition of specific
reagents or by freezing. This is particularly important in the case of highly unstable
molecules, such as mRNA. By contrast, although data regarding protein markers are sparse,
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for the majority of such proteins the process of freezing of samples for batch processing
does not appear to affect levels observed [68].
Assays must be sufficiently inexpensive, both to carry out and in terms of equipment,
expertise or reagents, in order to allow repeated use in routine surveillance.
The process of identifying clinically informative biomarkers typically involves comparison
with an existing measure that is considered to be the ‘gold standard’ (something that
definitively identifies a condition) [27]. However, in the context of CFPE, no such gold
standard exists. This situation greatly complicates the process of evaluating potential assays.
Nevertheless, the central role of the local inflammatory response in CFPE has led to the
investigation of a wide array of inflammatory mediators as biomarkers (as discussed by
Sagel et al. in 2007 [54]). Particular attention has been given to IL-8 [24,38,53,69–75],
neutrophil elastase [38,53,69–71,75,76] and myeloperoxidase [39,69,77–81] in sputum
samples. In each study, biomarker levels were elevated during CFPE, then decreased
following the initiation of antibiotic therapy. In addition to immunoenzymatic assays,
techniques such as 18F-fluorodeoxyglucose PET/CT imaging allow the direct determination
of the physical distribution of neutrophilic inflammation [82]. However, this method
remains too expensive and technically complex for routine use at this time.
As before, these studies have primarily sought to identify biomarkers that can provide
accurate and reliable measurement of the biologic activity surrounding CFPE and/or as a
sensitive marker of inflammation, primarily for use in assessing treatment strategies or
disease progression. Here, a wide range of host-derived biomarkers have the potential to be
useful. An increase in levels of these factors could be detectable prior to an elevation of
clinical signs and symptoms. However, this is likely only to occur once an upregulation in
inflammatory response has been established. As such, while having the potential to be
informative in the diagnosis of CFPE, disease progression and the evaluation of therapy,
these inflammatory biomarkers will be limited in their predictive power, because the point at
which inflammation is elevated may be too late to prevent irreversible lung damage. Instead,
in order to indicate the likely onset of CFPE, biomarkers that are associated with triggers of
inflammatory response upregulation must be identified. Consideration must therefore be
given to where such novel predictive biomarkers might be found.
CFPE-predictive biomarkers
A wide range of potential triggers have been proposed for the increased neutrophilic influx
that characterizes CFPE. Such a diversity of potential triggers may translate into a number of
different types of CFPE, each with different characteristics. For example, it has been
suggested that episodes of CFPE that result from bacterial and viral infection represent
distinct phenomena [83]. As such, separate diagnostic strategies may be required.
Infections caused by common respiratory viruses are associated with disease progression in
CF patients [33,83–86]. While such infections are symptomatically acute, there is evidence
that respiratory viruses may persist for extended periods in the airways of patients with a
range of chronic respiratory disease [87,88]. Therefore, it may be most appropriate to
analyze their presence in respiratory secretions through the enumeration of viral particles,
with data compared against a threshold level associated with respiratory symptoms, rather
than a simple presence/absence assay. Increasingly sophisticated molecular diagnostic
strategies are being developed for such analysis [89–92], making the application of these
assays a realistic proposition in the surveillance of CF patients.
Bacterial infections of the CF airways are typically chronic. The interactions between these
bacteria and the host, which may give rise to episodes of CFPE, therefore, are again unlikely
Rogers et al. Page 5
Expert Rev Mol Diagn. Author manuscript; available in PMC 2011 August 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
to be characterizable by presence/absence assays, and would require more detailed analysis.
For example, characterization of factors such as relative species abundance and gene-
expression profiles may be necessary [93,94]. However, in each instance, the response of the
host to changes in airway bacterial populations (and the resulting upregulation of the
inflammatory response among leukocytes and/or epithelial cells) should be the focus of
analysis (attempts to identify predictive biomarkers form part of the wider effort to
determine the nature of the relationship between bacteria and their products in the CF lower
airways, and the occurrence of CFPE). From a bacterial perspective, potential trigger
mechanisms may occur through different routes. Such mechanisms could include the
activation of neutrophils and epithelial cells when detecting the presence of bacterial cells in
the airways. Other mechanisms may involve the upregulation of the immune response
through the secretion of specific compounds by bacteria in the airways. In the case of the
former inflammatory response triggers, assays must focus on the detection and enumeration
of bacterial cells. For the other triggers, assays must be directed towards the measurement of
levels of either secreted compounds in the airway or the transcription of the genes that
encode them by bacterial cells (Figure 2).
Traditional, culture-based diagnostic microbiology is of limited use in reporting subtle
changes in airway bacterial populations because of the presence of slow-growing bacterial
variants [95,96] and potentially viable but nonculturable bacterial cells [97–100]. However,
the application of culture-independent quantitative PCR (Q-PCR) potentially offers a more
accurate means by which changes in bacterial numbers prior to the onset of CFPE can be
characterized [101], regardless of whether species are refractory to in vitro culture [102]. Q-
PCR technology is well validated and used widely in the characterization of bacteria in
clinical samples [103]. However, where clearance of material from the site of infection is
poor, as in the lower CF airways [104,105], the presence of nonviable cells and extra
cellular DNA can have a substantial impact on the accuracy of quantification by molecular
methods. In order to address this problem, new molecular protocols have been developed
that exclude from analysis any DNA not derived from viable bacterial cells [106]. These
protocols, based on the use of propidium monoazide photo-crosslinking chemistry to block
extracellular DNA or DNA from nonviable cells from serving as a template for PCR
reactions, have been adapted to the CF respiratory context [107]. Furthermore, they have
been shown to be capable of identifying short-term changes in bacterial levels in sputum not
detected by standard Q-PCR techniques, such as a reduction in bacterial density in CF
respiratory secretions following the intravenous administration of certain antibiotics [108].
Such approaches are rapid, relatively inexpensive and can be performed using automated
systems. While requiring further validation, such pretreatment of samples could provide a
basis for the routine surveillance of either total bacterial density in airway secretions, or the
densities of specific species or strains of particular interest using multiplex PCR reactions
[109].
It may be that it is the expression of particular traits by bacteria, rather than simply their
presence in the airways, that is key in triggering the onset of CFPE. In such circumstances,
early indications of CFPE onset might be derived from the determination of levels of
virulence behavior. Specific immunoenzymatic assays (ELISA) have previously been used
to directly determine levels of bacterially secreted compounds, such as Pseudomonas
aeruginosa elastase, exotoxin A and alkaline protease, in CF airway secretions [31]. While
not yet available as commercial kits, such assays may provide a rapid and relatively
inexpensive routine assay of bacterial virulence biomarkers. Real-time PCR assays could be
used to determine the transcription rates of virulence genes [110,111]. However, owing to
the instability of mRNA, such assays would be dependent on sample handling and, as such,
would be inappropriate for routine surveillance.
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In some cases, changes in the behavior of bacteria can be driven by alterations in the
physiochemical characteristics of the airways. Trace metals required for bacterial growth
may be particularly important in determining the way in which bacteria grow. For example,
lactoferrin, an iron-chelating protein abundant in human external secretions, blocks the
formation of biofilms by P. aeruginosa. Biofilms are a bacterial growth phenotype
implicated in CF respiratory pathogenesis [112,113]. Scavenging of trace metals by secreted
molecules such as lactoferrin may represent an important host antimicrobial strategy [72].
Direct spectrometric measurement of copper, zinc and iron has revealed elevated levels in
CF sputum compared with controls; furthermore, zinc levels in sputum decrease following
treatment of CFPE and derangements of this defense may impact lung disease in CF [72].
While requiring significant technological investment, elemental level analyses have the
advantage of not being affected by the activity of proteases [41,114]. However, further
investigation will be required in order to assess the clinical value of these measurements.
A number of secreted peptides that confer antimicrobial effects through the chelation of
trace metals may provide the basis for a more practical biomarker assay than trace-metal
measurement. For example, the neutrophil-secreted zinc chelator, calprotectin, is present in
high levels in CF airway secretions, and correlates with disease markers, including
neutrophil count [77,115,116]. The assays required to quantify calprotectin are
comparatively simple. If this biomarker is predictive of CFPE, the relative ease of
quantification would provide a range of practical benefits.
Expert commentary
As yet, there has been little investigation into whether inflammatory or microbial biomarkers
can provide an early indication of the likely onset of CFPE. This is partly owing to the fact
that many patients can remain stable for months or even years without experiencing a CFPE
episode. Substantial efforts are required to assemble the comprehensive data sets needed to
study and validate candidate markers by taking multiple airway secretion samples during
periods of pulmonary stability leading up to CFPE.
Several assays have now been validated analyzing potentially informative inflammatory
biomarkers in the assessment of CF sputum. The development of microbial biomarkers is far
less advanced. The utility of both types of measurement in predicting CFPE when applied to
longitudinally collected sample sets must now be investigated.
Owing to a variation in the way in which CFPEs manifest themselves between patients, and
even within the same patient [70], a panel of biomarkers may be more predictive than a
single measure. The use of composite biomarker panels has been shown to provide
improved diagnostic power in other contexts, including in the prediction of cardiovascular
disease risk [117] in relation to myocardial infarction and death [118]. Furthermore, since
the mechanisms by which CFPE occurs are not understood, it is potentially problematic to
select biomarkers on the basis of proposed mechanistic models. A composite CF lung
biomarker panel may therefore be more appropriate for CFPE prediction than any individual
biomarker [119].
Five-year view
Informing treatment strategies
The identification of biomarkers that provide an early indication of CFPE would represent a
major advancement in the management of CF airway infections. However, the impact that
such biomarkers could have is dependent on their ability to inform clinical decision-making,
and thus improve patient outcome. Current treatment strategies center around long-term
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maintenance therapy to retard disease progression and short-term therapy during periods of
CFPE to reduce symptoms. However, little consideration has been given to what the most
appropriate treatment would be if an impending pulmonary exacerbation was detected prior
to the upregulation of the local immune response. As efforts to measure biomarkers in CF
airway disease increase, such considerations will be necessary.
Microbial community
In addition to recognized CF pathogens, the CF lower airways often contain a complex
polymicrobial community [92–94,120–121]. It is therefore important to consider if and how
this wider community, consisting of bacteria, fungi, and eukaryotic viruses and phage
species, contributes to triggering CFPE, and, as such, presents potential targets for
diagnostic biomarker design. Microbial species may act as triggers, either through direct
interaction with the host, or through interactions with recognized CF pathogens such as P.
aeruginosa [92,122,123]. The potential complexity of these multispecies interactions
represents a significant challenge to predictive biomarker design and further elucidation is
required in order for them to inform this process.
Biomarker assay roll out
The value of performing certain mainstays of routine sputum diagnostics, such as the
determination of the antibiotic susceptibility of clinical isolates, are being called into
question [201]. The process of re-evaluating the components of CF sputum analysis provides
an opportunity to apply resources to emerging assays that may be clinically informative.
Furthermore, the expanding role being played by molecular diagnostics within healthcare
laboratories provides a skills base and infrastructure for the performance of increasingly
complex routine biomarker assays. Where assays can take advantage of sample types
already provided on a regular basis (e.g., for routine diagnostic microbiology), surveillance
through novel strategies might be possible without substantial disruption of existing patient
routines. However, while an exciting prospect, the identification of appropriate predictive
CFPE biomarkers requires further investigation.
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Box 1
Hypothesized triggers of cystic fibrosis pulmonary exacerbation
Bacterial
• Acquisition of new bacterial strains [84,124]
• Expansion of existing populations [125]
• Planktonic blooms [30]
• Increase in virulence gene expression [126]
• Shifts in bacterial community structure [93,94]
• Acquisition of new bacterial species, such as atypical Mycobacteria [127]
Environmental
• Particulate matter [34]
• Ozone [34]
Viral
• Respiratory viral infection [84,128,129]
• Human herpes virus [130]
Fungal
• Allergic bronchopulmonary aspergillosis [127]
• Colonization by Exophiala dermatitidis [131] or Candida albicans [132]
These triggers do not include structural changes in the airways, such as lobar/segmental
collapse, or nonadherence to treatment for factors outlined.
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Key issues
• A biomarker that objectively reflects disease activity, rather than relying on
clinical markers, would be a major advantage in the management of cystic
fibrosis pulmonary exacerbations.
• The identification of biomarkers that are predictive of pulmonary exacerbation
might allow early intervention prior to the establishment of an elevated
inflammatory response.
• The suspected infective nature of these events suggests that microbe-derived
biomarkers may be most useful.
• Potential assays can be based on the detection and enumeration of microbes, or
on measures of expression of clinically significant microbial traits.
• Both the accurate enumeration of key bacterial species and their gene-
expression markers are now possible through the application of molecular
genetic assays.
• While still in its infancy, this work has the potential to be useful in the
management of cystic fibrosis respiratory disease.
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Figure 1. Proposed path of cystic fibrosis pulmonary exacerbation onset
Conventionally, CFPE is diagnosed on the basis of an increase in the severity of clinical
signs and symptoms. Changes in these markers follow an upregulation of the local
inflammatory response. While molecular diagnostic assays based on components of the
inflammatory response offer an earlier and more specific indication of the onset of CFPE,
the ability to monitor factors associated with triggers of CFPE could allow intervention prior
to the infliction of airway damage.
CFPE: Cystic fibrosis pulmonary exacerbation; MW: Molecular weight.
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Figure 2. Passive and active potential microbial triggers for cystic fibrosis pulmonary
exacerbation, with suggested analytical points (white arrows) for onset prediction
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